| scholarly article | Q13442814 |
| P50 | author | Jianjiong Gao | Q43370984 |
| Carol Aghajanian | Q91946596 | ||
| P2093 | author name string | Kathleen Moore | |
| David M O'Malley | |||
| Don S Dizon | |||
| Douglas A Levine | |||
| Robert A Soslow | |||
| Heather A Lankes | |||
| Matthew A Powell | |||
| Angeles Alvarez Secord | |||
| Krishnansu S Tewari | |||
| Fanny Dao | |||
| Jay W Carlson | |||
| Ashley Stuckey | |||
| David P Bender | |||
| Virginia Filiaci | |||
| P2860 | cites work | VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing | Q24628978 |
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Integrated genomic characterization of endometrial carcinoma | Q28289962 | ||
| Wnt signalling and the mechanistic basis of tumour development | Q28301804 | ||
| Fast and accurate long-read alignment with Burrows-Wheeler transform | Q29547193 | ||
| Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study | Q30407709 | ||
| beta-Catenin regulates vascular endothelial growth factor expression in colon cancer | Q31146861 | ||
| SomaticSniper: identification of somatic point mutations in whole genome sequencing data | Q34095911 | ||
| Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples | Q34327021 | ||
| Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study | Q35023418 | ||
| Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group | Q35172203 | ||
| Proposal for the use of progression-free survival in unblinded randomized trials | Q36826988 | ||
| Clinical response to everolimus in a patient with Hodgkin's lymphoma harboring a TSC2 mutation | Q37027094 | ||
| Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. | Q37278360 | ||
| Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study | Q37429034 | ||
| Use of mutation profiles to refine the classification of endometrial carcinomas. | Q37612253 | ||
| Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study | Q39499020 | ||
| Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study | Q39668107 | ||
| Immunohistochemical Profiling of Endometrial Serous Carcinoma. | Q39775470 | ||
| Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia | Q43708535 | ||
| A Multiple Comparison Procedure for Comparing Several Treatments with a Control | Q56838307 | ||
| Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium | Q63199181 | ||
| Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study | Q63199194 | ||
| Required duration and power determinations for historically controlled studies of survival times | Q69583298 | ||
| Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma | Q85449603 | ||
| Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer | Q87215586 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bevacizumab | Q413299 |
| endometrial cancer | Q944777 | ||
| P304 | page(s) | 274-281 | |
| P577 | publication date | 2018-05-24 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer | |
| P478 | volume | 150 |
| Q104615269 | Angiogenesis in endometrial carcinoma: Therapies and biomarkers, current options, and future perspectives |
| Q91068249 | Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial |
| Q89999729 | Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation |
| Q61808759 | Divaricoside Exerts Antitumor Effects, in Part, by Modulating Mcl-1 in Human Oral Squamous Cell Carcinoma Cells |
| Q64270860 | Immunotherapy in endometrial cancer: new scenarios on the horizon |
| Q64112090 | Major clinical research advances in gynecologic cancer in 2018 |
| Q90550253 | PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer |
| Q89515061 | Progress in endometrial cancer: Contributions of the former Gynecologic Oncology Group |
| Q64898254 | Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer. |
| Q92780877 | Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q92365276 | The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report |
| Q90090414 | The role of omentectomy in the surgical treatment of uterine serous carcinoma |
Search more.